Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002357 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
A Phase 2 study, sponsored by Hoechst Marion Roussel.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00002357: Completed Phase 2 study, sponsored by Hoechst Marion Roussel.
NCT00002357 is a Phase 2 study that has completed, run by Hoechst Marion Roussel. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002357, a Phase 2 study, has completed, sponsored by Hoechst Marion Roussel.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
Interventions
- DRUG Zidovudine
- DRUG HBY 097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002357
The ClinicalTrials.gov registry entry for NCT00002357 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoechst Marion Roussel, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002357 about?
NCT00002357 is a clinical study titled "The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms". To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
What is the current status of trial NCT00002357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants.
What interventions are being tested in trial NCT00002357?
The interventions under investigation include: Zidovudine (DRUG), HBY 097 (DRUG).
Who is sponsoring clinical trial NCT00002357?
This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.